Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
12:00pm, Monday, 08'th Jun 2020
Esperion (ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare Confere
Why Is Esperion Therapeutics (ESPR) Down 1.5% Since Last Earnings Report?
03:31pm, Friday, 05'th Jun 2020
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy
04:00pm, Thursday, 04'th Jun 2020
Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 1)
Adaptimmune Therapeutics PLC...
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
12:00pm, Wednesday, 27'th May 2020
Esperion (ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference 202
Esperion: Early Commercial Success Supports A Buy At These Prices (NASDAQ:ESPR)
05:25pm, Tuesday, 19'th May 2020
Esperion's NEXLETOL and NEXLIZET are affordable, convenient, oral, once-daily, non-statin, LDL-C medicines recently approved by the FDA and European Commission.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10:00pm, Friday, 15'th May 2020
Esperion (ESPR) today announced that, on May 15, 2020, the Compensation Committee of Esperion’s Board of Directors granted 88,902 restricted stock units (RSUs) to 194 new colleagues under Esperion�
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 56'5(c)(4)
12:00am, Friday, 15'th May 2020Esperion Therapeutics' Festive Q1 2020 Earnings Call
10:28am, Wednesday, 13'th May 2020
Esperion is a true specialist focused on its niche mission of lipid management. The company's Q1 2020 earnings call reveled in product approvals and launches fo
Analysts Are Upgrading Esperion Therapeutics, Inc. (NASDAQ:ESPR) After Its Latest Results
06:49pm, Friday, 08'th May 2020
Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors will be delighted, with the company turning in some strong numbers...
Eye-Catching Quarterly Results From a Trio of Companies
12:38pm, Friday, 08'th May 2020
The first-quarter reports from Camping World, Esperion Therapeutics and BioDelivery Sciences were impressive amid coronavirus disruption.
